ArticleNeurochemical research2026
Targeting PAI-1 with TM5441 Mitigates Chronic Social Stress-Induced Anxiety-Like Behavior and Stress-Induced Increases in Ethanol Intake and Preference.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Chronic stress promotes alcohol use and relapse, yet the mechanisms linking stress-induced anxiety to excessive ethanol consumption remain poorly understood. Plasminogen activator inhibitor-1 (PAI-1), a stress-responsive regulator of neuroplasticity, has recently emerged as a potential therapeutic target; however, its role in stress-induced alcohol-related behaviors remains unknown. This study investigated whether TM5441, a selective inhibitor of plasminogen activator inhibitor-1 (PAI-1), modulates anxiety-like behavior and ethanol consumption following chronic social stress. Male mice were subjected to social defeat chronic stress (SDCS) and treated with TM5441. Behavioral assessments included the elevated plus maze (EPM), open field test (OFT), and two-bottle choice paradigms to assess voluntary intake of ethanol, saccharin, and quinine. Blood ethanol concentration (BEC) was measured to evaluate pharmacokinetic parameters. TM5441 significantly attenuated SDCS-induced anxiety-like behaviors and restored stress-induced increases in ethanol intake and preference toward control levels. These effects were specific to ethanol, as neither TM5441 nor stress altered saccharin or quinine consumption. Importantly, pharmacokinetic analyses revealed no differences in ethanol absorption or clearance, and BEC did not correlate with ethanol intake or preference, indicating that the observed behavioral effects are unlikely to result from differences in ethanol pharmacokinetics. Correlational analyses supported a functional link between anxiety-like behavior and increased ethanol consumption under stress. Together, these findings suggest that PAI-1 may contribute to the link between stress-induced anxiety and alcohol consumption and support further investigation of PAI-1 as a potential target for stress-related alcohol use disorders.
Indexed as
Identifiers
42627431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.